Head-to-Head Visual Comparison between Brain Perfusion SPECT and Arterial Spin-Labeling MRI with Different Postlabeling Delays in Alzheimer Disease

T. Kaneta, O. Katsuse, T. Hirano, M. Ogawa, K. Yoshida, T. Odawara, Y. Hirayasu, and T. Inoue

ABSTRACT

BACKGROUND AND PURPOSE: Arterial spin-labeling MR imaging has been recently developed as a noninvasive technique with magnetically labeled arterial blood water as an endogenous contrast medium for the evaluation of CBF. Our aim was to compare arterial spin-labeling MR imaging and SPECT in the visual assessment of CBF in patients with Alzheimer disease.

MATERIALS AND METHODS: In 33 patients with Alzheimer disease or mild cognitive impairment due to Alzheimer disease, CBF images were obtained by using both arterial spin-labeling–MR imaging with a postlabeling delay of 1.5 seconds and 2.5 seconds (PLD_{1.5} and PLD_{2.5}, respectively) and brain perfusion SPECT. Twenty-two brain regions were visually assessed, and the diagnostic confidence of Alzheimer disease was recorded.

RESULTS: Among all arterial spin-labeling images, 84.9% of PLD_{1.5} and 9% of PLD_{2.5} images showed the typical pattern of advanced Alzheimer disease (ie, decreased CBF in the bilateral parietal, temporal, and frontal lobes). PLD_{1.5}, PLD_{2.5}, and SPECT imaging resulted in obviously different visual assessments. PLD_{1.5} showed a broad decrease in CBF, which could have been due to an early perfusion. In contrast, PLD_{2.5} did not appear to be influenced by an early perfusion but showed fewer pathologic findings than SPECT.

CONCLUSIONS: The distinctions observed by us should be carefully considered in the visual assessments of Alzheimer disease. Further studies are required to define the patterns of change in arterial spin-labeling–MR imaging associated with Alzheimer disease.

ABBREVIATIONS: AD = Alzheimer disease; ASL = arterial spin-labeling; MCI = mild cognitive impairment; MMSE = Mini-Mental State Examination; PLD = postlabeling delay; PLD_{1.5} = postlabeling delay of 1.5 seconds; PLD_{2.5} = postlabeling delay of 2.5 seconds

For the imaging diagnosis of Alzheimer disease (AD), CBF is typically evaluated with brain perfusion SPECT.^{1,2} MR imaging is also commonly performed, chiefly for the evaluation of atrophy and ischemic changes in the brain. Obtaining these images simultaneously would be significantly beneficial to both patients and caregivers. Arterial spin-labeling (ASL) MR imaging has been recently developed as a noninvasive technique with magnetically labeled arterial blood water as an endogenous contrast medium for the evaluation of CBF.^{3–6} Several studies have reported interesting perfusion comparisons between patients with

various forms of dementia and demographically matched healthy controls. Both AD and mild cognitive impairment (MCI) have been associated with hypoperfusion in the middle occipital areas, medial temporal lobe, and especially the parietal lobe.⁷ Similar hypoperfusion has been reported in the posterior cingulate and precuneus, in addition to frontal and parietal regions.^{8,9} ASL-MR imaging is a potentially useful tool for the differential diagnosis of dementia.^{10,11} However, most studies have performed voxelwise or ROI analyses to detect abnormal findings in patients with AD compared with healthy patients or those with other forms of dementia. To date, only a few studies of AD have focused on visual assessment with ASL-MR imaging, mainly because of the lack of established criteria for using ASL-MR imaging to diagnose AD.

Pseudocontinuous ASL, the most common form of ASL, is a distinct form of pulsed and continuous labeling and is recommended for clinical imaging by the International Society for Magnetic Resonance in Medicine Workshop on Perfusion Imaging.¹² For ASL imaging, arterial water in the neck is labeled with a radiofrequency pulse and the brain is imaged after a fixed time interval, which is termed the postlabeling delay (PLD) and is the key parameter of ASL imaging. However, the optimal PLD for the

Received September 15, 2016; accepted after revision March 24, 2017.

From the Departments of Radiology (T.K., T.H., M.O., K.Y., T.I.) and Psychiatry (O.K., T.O., Y.H.), Yokohama City University, Yokohama, Japan.

We declare that all human and animal studies have been approved by the institutional review board of Yokohama City University School of Medicine and have therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. We declare that all patients gave informed consent prior to inclusion in this study.

Please address correspondence to Tomohiro Kaneta, MD, PhD, Department of Radiology, Yokohama City University, 3-9 Fukuura, Kanazawa-ku, Yokohama, 236-0004 Japan; e-mail kaneta@yokohama-cu.ac.jp

<http://dx.doi.org/10.3174/ajnr.A5238>

FIG 1. The regions used for scoring brain images. We evaluated 22 regions located at the levels of the vertex, lateral ventricle, basal ganglia, and cerebellum. The raters scored each region with a 4-point scale, where 0 is a normal CBF, 1 is a mild decrease, 2 is a moderate decrease, and 3 is a severe decrease.

evaluation of patients with dementia is unknown. Many previous studies of AD have used a PLD of 1.5 seconds (PLD_{1.5}),^{13,14} while others have used 2.0 seconds.¹⁵ The International Society for Magnetic Resonance in Medicine Workshop recommends 2.0 seconds for adult clinical patients,¹² but a longer PLD might be appropriate for elderly patients due to their relatively slow blood flow. In the present study, we performed a clinical visual assessment to compare the CBF images obtained by using ASL-MR imaging or brain perfusion SPECT in patients with AD. PLDs of 1.5 and 2.5 seconds (PLD_{2.5}) were used for ASL-MR imaging.

MATERIALS AND METHODS

We recruited 33 patients who underwent brain MR imaging and SPECT for the diagnosis of AD or MCI due to AD between September 2015 and June 2016. Patients with AD met the criteria of the National Institute of Neurological and Communicative Disorders and Stroke–Alzheimer Disease and Related Disorders Association for probable AD.¹⁶ Patients were excluded from the study if they had a significant history of psychiatric or neurologic disorders other than AD, including stroke, head injury, epilepsy, psychiatric disorders, alcohol abuse, and other serious medical conditions. All patients underwent MR imaging, SPECT, and standard dementia screening, which included a medical history and Mini-Mental State Examination (MMSE) and neuropsychological testing. SPECT and MR imaging were performed ≤1 month apart. The local institutional review board approved the study, and all subjects provided written informed consent.

MR Imaging

MR imaging was performed with a 3T MR imaging system (Discovery 750w; GE Healthcare, Milwaukee, Wisconsin) and a 12-channel head coil. Structural imaging for anatomic information was performed with a sagittal 3D T1-weighted sequence (TR = 6.6 ms, TE = 2 ms, flip angle = 14°, matrix = 256 × 256, 170 sections, voxel size = 1.0 × 0.9 × 0.9 mm³, FOV = 23 × 23 cm) with an acquisition time of 6 minutes.

A whole-brain pseudocontinuous ASL 3D perfusion sequence was acquired (3D fast spin-echo acquisition with background suppression). The imaging protocol with PLD_{1.5} was TR = 4641 ms, TE = 10.7 ms, locations = 36, FOV = 23 × 23 cm, voxel size = 2 × 2 × 4 mm³, labeling duration = 1.5 seconds, NEX = 1, and an acquisition time of 1 minute 33 seconds. The imaging protocol with PLD_{2.5} was TR = 5336 ms, TE = 10.7 ms, and

Table 1: Demographic and neuropsychological summary of the participants^a

	AD	MCI due to AD
Age (yr)	77.1 (7.7)	78.2 (5.6)
No. of patients	14	19
Sex (M/F)	3:11	8:11
MMSE score	16.9 (3.0) ^b	25.2 (2.6) ^b

^a Data are presented as mean (±SD).

^b There was a significant difference in the MMSE score ($P < .01$) between AD and patients with AD-induced MCI.

NEX = 2. All other parameters were the same, and the acquisition time was 2 minutes 51 seconds.

Brain Perfusion SPECT

The SPECT scans began 15 minutes after the intravenous injection of 148 MBq of iodine 123 *N*-isopropyl-*p*-iodoamphetamine (¹²³I-IMP) (Nihon Medipysics, Hyogo, Japan) and were performed for 30 minutes by using a SPECT/CT scanner (Symbia T16; Siemens, Erlangen, Germany). The SPECT scans were acquired by using low-medium-energy general purpose collimation, a 128 × 128 matrix of 3.3-mm pixel size, and 300 s/rotation in a continuous-rotation mode. SPECT reconstruction was performed with a Butterworth filter for filtered back-projection with a cutoff = 0.35/cm and an order of 8. A uniform attenuation correction was performed by using the Chang method, with μ = 0.11.

Visual Assessment

Two board-certified radiologists who are also nuclear medicine physicians with >10 years of experience in reading MR imaging and SPECT brain images and 2 years of experience reading ASL-MR imaging independently reviewed the images obtained in the present investigation without the clinical information of the patient. SPECT and ASL-MR imaging were shown with a section thickness of 6.6 and 6.4 mm, respectively. We used the scoring sheet shown in Fig 1 to assess 22 brain regions. The regions were located at the levels of the vertex, lateral ventricle, basal ganglia, and cerebellum. The raters scored each region by using a 4-point scale, in which zero indicated normal CBF; 1, a mild decrease; 2, a moderate decrease; and 3, a severe decrease. The diagnostic confidence of AD was also scored between 0 and 4, in which 0 indicated definitely not AD; 1, probably not AD; 2, undetermined; 3, probably AD; and 4, definitely AD. ASL-MR images were displayed in

Table 2: The results of visual assessments for the diagnosis of AD

	Overall Positive Rate (%)			Positive Rate in AD (%)			Positive Rate in MCI (%)		
	PLD _{1.5}	PLD _{2.5}	SPECT	PLD _{1.5}	PLD _{2.5}	SPECT	PLD _{1.5}	PLD _{2.5}	SPECT
Rater 1	87.9	9.1	69.7	92.9	14.3	92.9	84.2	28.6	52.6
Rater 2	97.0	12.1	90.1	100	28.6	92.9	94.7	0	89.5
Agreement	84.8	3.0	66.7	92.9	7.1	85.7	84.2	0	52.6

FIG 2. The comparisons of the total scores of the 2 raters for PLD_{1.5}, PLD_{2.5}, and SPECT images. The Friedman analysis of variance showed a significant difference among all 3 groups ($P < .01$), and the Wilcoxon test showed a significant difference between the 2 raters for the PLD_{1.5}, PLD_{2.5}, and SPECT total scores ($P < .01$).**Table 3: Interrater agreement**

	κ Statistic	
	5-Point Scoring	Positive or Negative for AD Diagnosis
PLD _{1.5}	0.033	0.3694
PLD _{2.5}	0.141	0.203
SPECT	0.010	0.195

gray-scale and in color-scale fused with T1-weighted images. SPECT images were displayed in color.

Statistical Analysis

The interrater variability was assessed for the diagnostic confidence of AD by using the κ statistic. The diagnostic confidence was evaluated with not only the 2-point scale but also positive (3 and 4) or negative (0–2) scores for AD diagnosis. The total scores for SPECT, PLD_{1.5}, and PLD_{2.5} from each rater were analyzed by using a Friedman test. Data were analyzed in Excel (Microsoft, Redmond, Washington) and JMP12 (SAS, Cary, North Carolina). A $P < .01$ was statistically significant.

RESULTS

Demographic Findings

Patient demographics are shown in Table 1, including age, the male-to-female ratio, and MMSE scores. There was no difference in age, but a significant difference in MMSE ($P < .01$) was observed between patients with AD and those with AD-induced MCI.

Visual Assessment

Table 2 shows the results of the visual assessment as the percentage of patients diagnosed with AD (score of 3 or 4) for each rater. The agreement concerning the percentage of patients with an AD

diagnosis between the 2 raters is also shown. These results are presented for 3 groups: namely, the total population, the AD group (MMSE ≤ 21), and the AD-induced MCI group (MMSE > 21). Both raters observed that for the total population, the AD group, and the AD-induced MCI group, PLD_{1.5} imaging had the highest positive rate for AD diagnosis, while PLD_{2.5} imaging had the lowest. Moreover, the positive rate for AD diagnosis was higher for the AD group than for the MCI group (Table 2). The Friedman analysis of variance test revealed a significant difference in total scores among all 3 imaging modalities ($P < .01$), and the Wilcoxon test revealed a significant difference between

the 2 groups in the assessment of PLD_{1.5}, PLD_{2.5}, and SPECT images ($P < .01$) (Fig 2). There were no significant differences between the AD and AD-induced MCI groups in the total score for 3 imaging modalities. The interrater agreements were low for both the 5-point or 2-alternative scoring of AD (Table 3).

Case Presentations

Case 1 was an 86-year-old woman with AD. Her MMSE score was 14. The ASL-MR imaging and SPECT images for this patient are shown in Fig 3. Case 2 was an 83-year-old woman with AD. Her MMSE score was 19. The images for this patient are shown in Fig 4. Case 3 was a 73-year-old woman with MCI due to AD. Her MMSE score was 23. The images for this patient are shown in Fig 5.

DISCUSSION

We clearly observed differences in the visual assessments of PLD_{1.5}, PLD_{2.5}, and SPECT images. The total scores of the 2 raters were highest for the PLD_{1.5} images; this finding suggests a large decrease in CBF. Indeed, these scores were diminished or ambiguous in PLD_{2.5} images. SPECT findings were of intermediate severity compared with those for the PLD_{1.5} and PLD_{2.5} images. These findings appeared to have a profound effect on the diagnostic confidence of AD—that is, for both raters, the positive rate for AD diagnosis was very high (approximately 90%) with a high agreement rate for PLD_{1.5} images, while the diagnostic confidence of AD was low for PLD_{2.5} images with a low agreement rate. In addition, SPECT images were associated with a moderately high diagnostic confidence and agreement rate. The positive rate of AD diagnosis for the SPECT images in the present investigation was consistent with that of previous studies.^{1,2}

In the present study, the PLD_{1.5} images often showed marked

FIG 3. An 86-year-old woman with AD. The patient had an MMSE score of 14. Axial images of T2-weighted MR imaging (A), ASL-MR imaging with PLD_{1.5} in a color-scale fused with T1-weighted MR imaging (B), ASL-MR imaging with PLD_{2.5} in a color-scale fused with T1-weighted MR imaging (C), and brain perfusion SPECT at the level of the parietal lobe, corona radiata, basal ganglia, and cerebellum (D). Both raters indicated a score of 4 (definitely AD) for PLD_{1.5} and SPECT and 1 (probably not AD) for PLD_{2.5}.

bilateral decreases in signal intensity in the frontal and temporo-parietal lobes, even for patients with AD-induced MCI, but these findings were mostly not present in the PLD_{2.5} images (case 3, Fig 5). A previous study using PLD_{1.5} for patients with cerebrovascular disease reported a low ASL signal with surrounding cortical areas showing a high signal intensity in the middle cerebral artery–anterior cerebral artery and middle cerebral artery–posterior cerebral artery borderzones. This phenomenon was termed the “borderzone sign”.¹⁷ Another recent study evaluated the performance of PLD_{1.5} compared with SPECT in patients with AD and reported that PLD_{1.5} images frequently showed the border-

zone sign.¹⁸ Our results suggest the presence of the borderzone sign for PLD_{1.5}, but not PLD_{2.5}. The presence of the borderzone sign in ASL-MR images with a short PLD, but not in those with a long PLD, could have been due to an early perfusion adjacent to the main cerebral arteries. In fact, our PLD_{2.5} images did not frequently show such a broad decrease in CBF, and neither did the SPECT images.

In the present study, the PLD_{2.5} images frequently showed only minor pathologic findings with a low image contrast. Generally, a long PLD decreases the signal-to-noise ratio because of T1 relaxation. Thus, we doubled the number of excitations for

FIG 4. An 83-year-old woman with AD. The patient had an MMSE score of 19. Axial images of T2-weighted MR imaging (A), fused T1-weighted and PLD_{1.5} ASL-MR imaging (B), fused T1-weighted and PLD_{2.5} ASL-MR imaging (C), and brain perfusion SPECT (D). Both raters indicated a score of 4 for PLD_{1.5} and 2 (undetermined) for PLD_{2.5}. One rater indicated a score of 3 (probably AD) and another rater indicated a score of 4 for SPECT.

PLD_{2.5} compared with PLD_{1.5}; however, a greater number of excitations or the modification of some other parameter might be necessary to improve image contrast and quality.

A previous study comparing PET using FDG and ASL-MR imaging using PLD_{1.5} in patients with AD¹⁹ reported that both methods showed similar regional abnormalities and have comparable diagnostic accuracy in AD. The PLD_{1.5} images of this previous study were different from ours, which did not show decreased CBF in the frontal lobes. The findings of this previous study also contradict those in another study that reported decreased CBF in

the frontal lobes of patients with AD.²⁰ Another study performed multidelay multiparametric ASL for patients with stroke; however, their PLD_{1.5} images did not show decreased CBF in the frontal lobes but resembled those of PLD_{2.5} images.²¹ Such conflicting results between these studies may be due to scanner differences, parameters other than PLD, or other experimental differences.

There is a strong link between brain metabolism and CBF.²² Thus, SPECT images have been generally interpreted in a manner similar to that of FDG-PET. However, as our results show, ASL-MR images can change depending on the PLD and show

FIG 5. A 73-year-old woman with MCI. The patient had an MMSE score of 23. Axial images of T2-weighted MR imaging (A), fused T1-weighted and PLD_{1.5} ASL-MR imaging (B), fused T1-weighted and PLD_{2.5} ASL-MR imaging (C), and brain perfusion SPECT (D). Both raters scored 4 for PLD_{1.5}. However, 1 rater indicated a score of 1 (probably not AD) for PLD_{2.5} and 2 for SPECT, while another rater indicated a score of 0 (definitely not AD) for PLD_{2.5}, and 1 for SPECT.

significantly different findings from SPECT. The use of FDG criteria for ASL-MR imaging diagnosis of AD increases the risk of over- or underdiagnosis. Further studies will be needed to establish the optimal conditions for ASL-MR imaging in the diagnosis of AD and to define the dynamic temporal patterns of ASL-MR images associated with the development of AD.

Regarding the differentiation of AD and AD-induced MCI, we did not observe significant differences in total scores of the 3 modalities between the AD and AD-induced MCI groups. The positive rates for AD diagnosis for the AD group were slightly higher than those for the AD-induced MCI group; however, the differ-

ences were small. Further studies are required to clarify the usefulness of ASL for the discrimination of AD and AD-induced MCI.

The interrater agreements were low in the present study, even for the 2-alternative scoring method. The participants in our study had relatively high MMSE scores. Only 1 participant had an MMSE score of <10, and 5 of the participants had scores of <15, which could have resulted in a low interrater agreement.

The present study has several limitations. First, the sample size was small; a larger sample would produce more reliable results. Second, we did not perform MR angiography due to tight time

constraints. Third, no images of cognitively healthy participants were used as controls; thus, we could not evaluate the accuracy of the visual-based diagnosis. Finally, an optimal PLD could not be determined in the present study. These limitations should be considered for future research.

CONCLUSIONS

Significant differences in visual assessments were observed for PLD_{1.5}, PLD_{2.5}, and SPECT images. PLD_{1.5} images showed a robust decrease in CBF, which could have been due to an early perfusion. In contrast, PLD_{2.5} did not appear to be influenced by an early perfusion but showed fewer pathologic findings than SPECT. Visual assessment of AD should be performed with attention to these distinctions. Further studies are required to define the dynamic temporal ASL-MR imaging pattern associated with AD.

ACKNOWLEDGMENTS

We thank Mr. Yuki Koyo for his assistance with data collection and analyses, Dr. Ayako Hino for reading images, and Mr. Naoki Hirata for his advice on the processing of ASL-MR imaging.

REFERENCES

1. Jagust W, Thisted R, Devous MD Sr, et al. **SPECT perfusion imaging in the diagnosis of Alzheimer's disease: a clinical-pathologic study.** *Neurology* 2001;56:950–56 CrossRef Medline
2. Bonte FJ, Weiner MF, Bigio EH, et al. **Brain blood flow in the dementias: SPECT with histopathologic correlation in 54 patients.** *Radiology* 1997;202:793–97 CrossRef Medline
3. Dai W, Lopez OL, Carmichael OT, et al. **Mild cognitive impairment and Alzheimer disease: patterns of altered cerebral blood flow at MR imaging.** *Radiology* 2009;250:856–66 CrossRef Medline
4. Chao LL, Pa J, Duarte A, et al. **Patterns of cerebral hypoperfusion in amnesic and dysexecutive MCI.** *Alzheimer Dis Assoc Disord* 2009;23:245–52 CrossRef Medline
5. Johnson NA, Jahng GH, Weiner MW, et al. **Pattern of cerebral hypoperfusion in Alzheimer disease and mild cognitive impairment measured with arterial spin-labeling MR imaging: initial experience.** *Radiology* 2005;234:851–59 CrossRef Medline
6. Asllani I, Habeck C, Scarmeas N, et al. **Multivariate and univariate analysis of continuous arterial spin labeling perfusion MRI in Alzheimer's disease.** *J Cereb Blood Flow Metab* 2008;28:725–36 CrossRef Medline
7. Alexopoulos P, Sorg C, Förstner A, et al. **Perfusion abnormalities in mild cognitive impairment and mild dementia in Alzheimer's disease measured by pulsed arterial spin labeling MRI.** *Eur Arch Psychiatry Clin Neurosci* 2012;262:69–77 CrossRef Medline
8. Yoshiura T, Hiwatashi A, Noguchi T, et al. **Arterial spin labelling at 3-T MR imaging for detection of individuals with Alzheimer's disease.** *Eur Radiol* 2009;19:2819–25 CrossRef Medline
9. Mak HK, Chan Q, Zhang Z, et al. **Quantitative assessment of cerebral hemodynamic parameters by QUASAR arterial spin labeling in Alzheimer's disease and cognitively normal elderly adults at 3-Tesla.** *J Alzheimers Dis* 2012;31:33–44 CrossRef Medline
10. Du AT, Jahng GH, Hayasaka S, et al. **Hypoperfusion in frontotemporal dementia and Alzheimer disease by arterial spin labeling MRI.** *Neurology* 2006;67:1215–20 CrossRef Medline
11. Steketee RM, Bron EE, Meijboom R, et al. **Early-stage differentiation between presenile Alzheimer's disease and frontotemporal dementia using arterial spin labeling MRI.** *Eur Radiol* 2016;26:244–53 CrossRef Medline
12. Alsop DC, Detre JA, Golay X, et al. **Recommended implementation of arterial spin-labeled perfusion MRI for clinical applications: a consensus of the ISMRM perfusion study group and the European consortium for ASL in dementia.** *Magn Reson Med* 2015;73:102–16 CrossRef Medline
13. Chen Y, Wolk DA, Reddin JS, et al. **Voxel-level comparison of arterial spin-labeled perfusion MRI and FDG-PET in Alzheimer disease.** *Neurology* 2011;77:1977–85 CrossRef Medline
14. Vercluyte S, Lopes R, Lenfant P, et al. **Cerebral hypoperfusion and hypometabolism detected by arterial spin labeling MRI and FDG-PET in early-onset Alzheimer's disease.** *J Neuroimaging* 2016;26:207–12 CrossRef Medline
15. Binnewijzend MA, Kuijper JP, Benedictus MR, et al. **Cerebral blood flow measured with 3D pseudocontinuous arterial spin-labeling MR imaging in Alzheimer disease and mild cognitive impairment: a marker for disease severity.** *Radiology* 2013;267:221–30 CrossRef Medline
16. McKhann G, Drachman D, Folstein M, et al. **Clinical diagnosis of Alzheimer disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Service Task Force on Alzheimer Disease.** *Neurology* 1984;34:939–44 CrossRef Medline
17. Zaharchuk G, Bammer R, Straka M, et al. **Arterial spin-label imaging in patients with normal bolus perfusion-weighted MR imaging findings: pilot identification of the borderzone sign.** *Radiology* 2009;252:797–807 CrossRef Medline
18. Takahashi H, Ishii K, Hosokawa C, et al. **Clinical application of 3D arterial spin-labeled brain perfusion imaging for Alzheimer disease: comparison with brain perfusion SPECT.** *AJNR Am J Neuroradiol* 2014;35:906–11 CrossRef Medline
19. Musiek ES, Chen Y, Korczykowski M, et al. **Direct comparison of fluorodeoxyglucose positron emission tomography and arterial spin labeling magnetic resonance imaging in Alzheimer's disease.** *Alzheimers Dement* 2012;8:51–59 CrossRef Medline
20. Raji CA, Lee C, Lopez OL, et al. **Initial experience in using continuous arterial spin-labeled MR imaging for early detection of Alzheimer disease.** *AJNR Am J Neuroradiol* 2010;31:847–55 CrossRef Medline
21. Wang DJ, Alger JR, Qiao JX, et al; UCLA Stroke Investigators. **Multi-delay multi-parametric arterial spin-labeled perfusion MRI in acute ischemic stroke: comparison with dynamic susceptibility contrast enhanced perfusion imaging.** *Neuroimage Clin* 2013;3:1–7 CrossRef Medline
22. Kuschinsky W. **Coupling of function, metabolism, and blood flow in the brain.** *Neurosurg Rev* 1991;14:163–68 CrossRef Medline